HOME >> BIOLOGY >> NEWS
Antibiotics may not be enough to stop recurrent gastric lymphoma caused by Helicobacter pylori

Stanford, CA -- Research led by Dr. Anne Mueller at Stanford University School of Medicine demonstrates that successful eradication of Helicobacter may not prevent future aggressive gastric lymphoma since resting B cells are left behind. The paper by Mueller et al., "The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma," appears in the September issue of The American Journal of Pathology.

Helicobacter pylori, a spiral bacterium of the stomach, infects more than half of the world's population. It is now widely accepted that, aside from gastritis and ulcers, H. pylori is also a causative agent of gastric lymphoma, specifically gastric B cell lymphoma of mucosa-associated lymphoid tissue (MALT). While antibiotic treatment eradicates the bacteria and promotes tumor regression, the effects of re-infection on disease are more severe.

To address the effects of re-infection and the role of immune cells in disease progression, Dr. Mueller's group used a mouse model of Helicobacter-induced MALT lymphoma that employs H. felis to mimic human disease in the mouse. Mice were infected with H. felis and maintained for 18 months before being assigned to one of three treatment groups: 1) no treatment (primarily infected), 2) antibiotic therapy to eradicate bacteria, or 3) antibiotic therapy followed by re-infection.

As expected, low-grade MALT lymphoma occurred in 35% of all infected animals. However, frank MALT lymphoma was more prevalent in re-infected animals (44%) than in primarily infected animals (25%). Transcription profiling identified B cell markers in mice that had been infected at any point in time, even after successful antibiotic treatment, suggesting that resting B cells remain in the gastric mucosa.

Lymphoid aggregates of re-infected animals also contained more proliferating cells than those of primarily infected or antibiotic-treated animals (46% vs. 23
'"/>

Contact: Audra Cox
acox@asip.org
301-634-7409
American Journal of Pathology
25-Aug-2005


Page: 1 2

Related biology news :

1. Antibiotics help combat dangerous tropical disease
2. Recycling is not enough -- we need to consume less
3. One Wwox isnt enough (to protect against cancer)
4. Its enough to turn your neighbors green
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. When Gleevec is not enough
7. Marine life stirs ocean enough to affect climate, says FSU study
8. Increase in drug development for killer diseases is not enough
9. Heart has enough oxygen to survive hypothermia, CPR crucial
10. Pepper component hot enough to trigger suicide in prostate cancer cells
11. Yale study: Not enough metals in earth to meet global demand

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2020)... ... May 29, 2020 , ... eInfochips, a leading provider of ... with EchoNous Inc. to develop the cloud-based connected health KOSMOS platform that has ... has been clinically tested versus expert measurements, yielding improved results in precision and ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology ... T cell engagers and TCR-based therapeutics, has implemented Genedata Biologics ® ...
(Date:5/21/2020)... ... ... Law Enforcement has always been a highly stressful career – serving to protect, ... and women put them constantly in harm’s way both from the criminal element as ... to face very high daily stress. Now, COVID-19 introduces another even greater degree of ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... , ... May 12, 2020 , ... ... for translational research, is bringing together thousands of industry leaders, clinicians, research scientists, ... highlights two plenary speakers, Carl June, MD, Director of the Center for Cellular ...
(Date:5/5/2020)... ... 05, 2020 , ... ProductLife Group has marked the next phase ... group after 13 years at Altran, where he was Group VP of Life Sciences ... being a Pharmacist, Xavier was involved in his early career in the development of ...
(Date:4/22/2020)... (PRWEB) , ... April 20, 2020 , ... ... offices in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila ... of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO ...
(Date:4/7/2020)... ... April 06, 2020 , ... Red Nucleus, a ... industry, has announced the release of at-home virtual learning resources for all client ... health and safety of our employees as we continue to implement measures to ...
Breaking Biology Technology:
Cached News: